QGenta
Employing novel heterocyclic chemistry to develop drugs to treat cancers and protein folding disorders
- Stage Product In Development
- Industry Biotechnology
- Location Aurora, CO, USA
- Currency USD
- Founded December 2008
- Employees 4
Company Summary
QGenta is an early stage biopharmaceutical company that undertakes preclinical development of molecular targeted therapeutics to treat cancers and pathologies caused by aberrant protein folding.
Team
-
David RossProfessor and Department Chairman
Professor and Department Chairman Skaggs School of Pharmacy, Department of Pharmaceutical Sciences, University of Colorado
-
Christopher J MoodySir Jesse Boot Professor
Sir Jesse Boot Professor School of Chemistry University of Nottingham
-
David SiegelResearch Associate Professor
Research Associate Professor, Skaggs School of Pharmacy, Department of Pharmaceutical Sciences, University of Colorado
-
Paul JaroszPharmaceutical Consultant
Advisors
-
Kendall Koenig & Oelsner PC Attention Kevin Gibson 999 Eighteenth Street, Suite 1825 North Tower Denver, CO 80202LawyerUnconfirmedRussell Baker, CPA, MT The Baker GroupAccountantUnconfirmed
Previous Investors
-
University of Nottingham, UKUnconfirmedState of Colorado (OEDIT)UnconfirmedUniversity of Colorado Technologies TransferUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.